Loading clinical trials...
Loading clinical trials...
Discover 23,284 clinical trials near Maryland. Find research studies in your area.
Showing 21261-21280 of 23,284 trials
NCT01629810
The purpose of this study is to test the effectiveness of whole body periodic acceleration for helping with symptoms of aches and pains suffered by many patients.
NCT00445549
Background: * Vandetanib is a drug that attacks a group of proteins on the surface of many cells, especially blood vessel cells and tumor cells. * Tumors require the development of new blood vessels in order to grow and spread. * In laboratory experiments, vandetanib slowed the growth of certain tumors and regulated their blood vessel growth. * In early clinical trials, some patients' tumors did not grow for a period of time while they were receiving vandetanib. Objectives: * To determine whether vandetanib can cause tumors to shrink or stabilize in some patients with ovarian cancer, fallopian tube cancer or primary peritoneal cancer. * To determine, by tumor biopsy, if features of the tumor change with vandetanib treatment may predict if the tumor will likely respond to vandetanib. Eligibility: * Women 18 years of age and older with ovarian, fallopian tube or primary peritoneal cancer that does not respond to standard treatment. Design: * Patients take vandetanib daily, by mouth in 28-day cycles until their disease worsens or they develop unacceptable side effects. * Tumor biopsies (surgical removal of a sample of tumor tissue) are done before starting vandetanib treatment and after 6 weeks of treatment. * Patients are followed in the clinic every 4 weeks during treatment for a physical examination, blood tests, and review of laboratory studies and side effects. * Patients have a computed tomography (CT) scan every 8 weeks to monitor tumor growth and magnetic resonance imaging (MRI) before starting vandetanib treatment, on the third day after taking vandetanib and 6 weeks into treatment. * Patients quality of life is assessed with regularly scheduled questionnaires.